STOCK TITAN

T2 Biosystems, Inc - TTOO STOCK NEWS

Welcome to our dedicated page for T2 Biosystems news (Ticker: TTOO), a resource for investors and traders seeking the latest updates and insights on T2 Biosystems stock.

T2 Biosystems, Inc. (Symbol: TTOO) is a pioneering company in the field of in vitro diagnostics, dedicated to improving patient health through advanced diagnostic products. The company’s core focus is on developing rapid diagnostic tools aimed at detecting sepsis-causing pathogens and antibiotic resistance genes. Sepsis, a condition that accounts for one out of two hospital deaths, is a primary target for T2 Biosystems.

Utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, the company has launched FDA-cleared products such as the T2Dx Instrument, T2Bacteria Panel, and T2Candida Panel. These products enable faster, more accurate detection of pathogens, allowing clinicians to make informed treatment decisions earlier. T2 Biosystems is also working on an array of other diagnostic solutions targeting hemostasis, bacteria, and Lyme disease. Notably, the T2Lyme Panel is slated for commercial launch in the third quarter of 2024.

Recent achievements highlight the company’s growth and stability. T2 Biosystems has recently achieved double-digit growth in sepsis product revenue and significantly reduced its total debt by approximately 80% over the past year. The company is a leader in the rapid detection of sepsis-causing pathogens, powered by its proprietary T2 Magnetic Resonance technology. These advancements not only promise to lower mortality rates but also aim to enhance patient outcomes and reduce healthcare costs.

T2 Biosystems is committed to fostering an innovative and inclusive work environment. The company actively seeks to attract and retain top talent, encouraging a culture of growth and excellence. For those interested in joining the mission to transform medical diagnostics, open positions can be found on their website.

Rhea-AI Summary

T2 Biosystems (NASDAQ:TTOO) announced on July 19, 2021, the issuance of inducement awards to eleven new employees under its Inducement Award Plan. The awards include options to purchase 321,000 shares with an exercise price of $1.06, the closing price on July 8, 2021. Options vest over four years, with 25% vesting after one year. This initiative aims to attract talent while complying with Nasdaq rules, supporting T2’s mission in rapid pathogen detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
none
-
Rhea-AI Summary

T2 Biosystems (NASDAQ:TTOO) is set to participate in three upcoming virtual conferences focusing on rapid diagnostic technology for bloodstream infections and sepsis. The conferences include the World Microbe Forum from June 20-24, the Sepsis Tech and Innovation 2021 on June 23, and the 31st European Congress of Clinical Microbiology & Infectious Diseases on July 12. CEO John Sperzel highlighted the significance of addressing sepsis, which accounts for nearly 20% of global deaths, emphasizing that their products, such as the T2Candida® and T2Bacteria® panels, offer rapid results crucial for effective management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
conferences
-
Rhea-AI Summary

T2 Biosystems (NASDAQ:TTOO) announced its 2021 Annual Meeting of Stockholders scheduled for June 25, 2021. The Board of Directors fully supports all proposals on the proxy and urges stockholders to participate. CEO John Sperzel emphasized the significance of these proposals in a video message available on the company's Investor Relations site. Stockholders of record as of April 28, 2021, are eligible to vote. Proxy materials and additional shareholder information can be accessed through the SEC's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
Rhea-AI Summary

T2 Biosystems (TTOO) reported strong financial results for Q1 2021, with total revenue rising 173% to $7.0 million, including product revenue surging 345% to $4.7 million. Sepsis test utilization in the U.S. increased by 85%, resulting in an annualized test run rate of approximately $111,000 per instrument. The company sold 4 T2Dx instruments, expanded its salesforce to 9 Regional Account Managers, and modified existing contracts to enhance product development. Despite a net loss of $(10.7) million, T2 holds $43.9 million in cash and expects full-year revenues between $24 million and $26 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
-
Rhea-AI Summary

T2 Biosystems (NASDAQ:TTOO) announced modifications to its contract with BARDA to speed up the development of key products including T2Biothreat, T2Resistance, and a comprehensive sepsis panel. The multi-year contract could be valued at up to $69.0 million. The changes allow for accelerated development of these vital panels designed to detect various pathogens and antibiotic resistance. The contract is part of a broader effort to enhance diagnostics and manage sepsis, significantly impacting patient outcomes by reducing diagnostic times and improving treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
none
-
Rhea-AI Summary

T2 Biosystems has announced a meta-analysis published in Expert Review of Medical Devices, demonstrating that its T2 Magnetic Resonance (T2MR) technology significantly reduces time to detection, species identification, and ICU and hospital stays for patients with bloodstream infections (BSIs). Key findings include a reduction of 81 hours in detection time and 77 hours in species identification compared to standard blood cultures. Patients receiving T2MR results were treated faster with targeted therapy, potentially lowering hospital costs by up to $25,000 per patient.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
none
Rhea-AI Summary

T2 Biosystems (NASDAQ:TTOO) will report its first quarter 2021 financial results after market close on May 6, 2021. A conference call will follow at 4:30 p.m. ET. T2 Biosystems specializes in the rapid detection of sepsis-causing pathogens, aiming to enhance patient care and reduce treatment costs. Their product lineup includes the T2Dx® Instrument and various diagnostic panels powered by proprietary T2 Magnetic Resonance technology. Interested parties can access the conference call via the company’s website or by phone.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.58%
Tags
conferences earnings
-
Rhea-AI Summary

T2 Biosystems (NASDAQ:TTOO) CEO John Sperzel has published a book detailing his personal battle with sepsis and a bloodstream infection. The book, titled Courage: Powerful Lessons in Leadership, Strength, and the Will to Succeed, aims to raise awareness of sepsis, which affects over 1.7 million Americans annually. The CDC reports sepsis costs the U.S. healthcare system more than $62 billion per year. Sperzel advocates for culture-independent rapid diagnostic tests to expedite treatment and potentially reduce mortality rates by 8% for each hour of delay.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
-
Rhea-AI Summary

T2 Biosystems (NASDAQ:TTOO) announced on March 26, 2021, the issuance of inducement awards to eighteen new employees, under its Inducement Award Plan. These awards include options to purchase 413,000 shares at an exercise price of $1.68, the closing price on March 25, 2021. The options vest over four years. T2 Biosystems specializes in rapid detection of sepsis-causing pathogens and aims to enhance patient care while reducing costs. The company continues to innovate with products like the T2Dx® Instrument and has a robust pipeline of future offerings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
none
Rhea-AI Summary

T2 Biosystems, Inc. (NASDAQ:TTOO) reported a strong financial performance for Q4 and full-year 2020, achieving total revenue of $18.1 million, a 118% increase from the previous year. Q4 revenue reached $7.8 million, growing 154% year-over-year. Product sales for Q4 were $5.8 million, a 273% increase. The company sold 57 T2Dx Instruments in 2020, doubling the U.S. installed base, and increased U.S. sepsis test utilization by 72%. The firm anticipates 2021 revenue between $24.0 million and $26.0 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.95%
Tags

FAQ

What is the current stock price of T2 Biosystems (TTOO)?

The current stock price of T2 Biosystems (TTOO) is $0.3589 as of December 23, 2024.

What is the market cap of T2 Biosystems (TTOO)?

The market cap of T2 Biosystems (TTOO) is approximately 7.4M.

What is T2 Biosystems, Inc. known for?

T2 Biosystems is known for its rapid diagnostic products that detect sepsis-causing pathogens and antibiotic resistance genes.

What are the core products of T2 Biosystems?

The core products include the T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, T2Resistance Panel, and T2Biothreat Panel.

What proprietary technology does T2 Biosystems use?

T2 Biosystems uses its proprietary T2 Magnetic Resonance platform, or T2MR®, for rapid pathogen detection.

What recent financial achievements has T2 Biosystems made?

T2 Biosystems has achieved double-digit growth in sepsis product revenue and reduced its total debt by approximately 80% over the past year.

When is the T2Lyme Panel expected to launch?

The T2Lyme Panel is anticipated to be commercially available in the third quarter of 2024.

Where can I find job opportunities at T2 Biosystems?

Job opportunities at T2 Biosystems can be found on their official website.

How does T2 Biosystems aim to impact healthcare?

T2 Biosystems aims to lower mortality rates, enhance patient outcomes, and reduce healthcare costs through its rapid diagnostic products.

Who can I contact for investor-related inquiries?

For investor-related inquiries, you can contact Philip Trip Taylor at Gilmartin Group via email at ir@T2Biosystems.com or phone at 415-937-5406.

What areas of unmet medical need is T2 Biosystems targeting?

T2 Biosystems is targeting unmet medical needs in sepsis, hemostasis, bacteria, and Lyme disease.

How does T2MR® technology benefit patient care?

T2MR® technology benefits patient care by enabling faster and more accurate detection of pathogens, leading to earlier and more targeted treatment decisions.

T2 Biosystems, Inc

Nasdaq:TTOO

TTOO Rankings

TTOO Stock Data

7.40M
8.59M
10.17%
73.51%
4.78%
Diagnostics & Research
Surgical & Medical Instruments & Apparatus
Link
United States of America
LEXINGTON